T-Dm1, a Novel Antibody-Drug Conjugate, Is Highly Effective Against Uterine and Ovarian Carcinosarcomas Overexpressing HER2

Clinical and Experimental Metastasis - Netherlands
doi 10.1007/s10585-014-9688-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Trastuzumab-Dm1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer

The Open Breast Cancer Journal
2009English

Resistance to the Antibody–Drug Conjugate T-Dm1 Is Based in a Reduction in Lysosomal Proteolytic Activity

Cancer Research
Cancer ResearchOncology
2017English

Antibody–Drug Conjugate Hits Elusive HER2 + Breast Tumors

Cancer Discovery
Oncology
2013English

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Balkan Medical Journal
Medicine
2016English

T-Dm1 Reduces HER2+ Breast Cancer Recurrence

Cancer Discovery
Oncology
2018English

Antibody-Drug Conjugates With HER2-targeting Antibodies From Synthetic Antibody Libraries Are Highly Potent Against HER2-positive Human Gastric Tumor in Xenograft Models

mAbs
AllergyImmunology
2018English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters

PLoS ONE
Multidisciplinary
2009English

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy